Lu-na-sin (loo nə sĭn)

A naturally-occurring soy peptide, discovered by UC Berkely scientist Dr. Alfredo Galvez in 1996 as a result of his research to improve the nutritional profile of soy protein.

What is the significance of lunasin in Reliv products?

  • The Lunasin peptide is contained in LunaRich®, a soy powder exclusive to Reliv products.
  • LunaRich® delivers five to ten times as much bioactive lunasin as ordinary soy powder.

What is epigenetics and how does it affect my health?

  • The genome is the blueprint of life, the DNA that makes you unique. The epigenome acts as a series of switches, telling the genome which genes to turn on and which to turn off.
  • This process of turning on and off is called “gene expression.”
  • While you cannot change your DNA, you can, through your lifestyle, influence how your genes are “expressed.”
  • Poor lifestyle means poor gene expression; healthy lifestyle means healthy gene expression.
  • Lunasin is one of the first dietary ingredients identified to affect gene expression and promote optimal health.

What are the cardio-vascular benefits attributed to Lunasin?

  • High blood total cholesterol levels and high LDL are proven risk factors for coronary heart disease.
  • In 1999, the Food and Drug Administration (FDA) approved a health claim for soy protein, noting that soy could lower blood total cholesterol and LDL or “bad” cholesterol levels.
  • Additionally, it was noted that soy protein offers these benefits without adversely affecting HDL or “good” cholesterol levels.
  • Further research by Alfredo F. Galvez sought to prove that lunasin is the active agent in soy responsible for these benefits.
  • Dr. Galvez produced a lunasin extract that is 100-200 times more potent than typical a soy isolate.
  • Dr. Galvez’s research proved lunasin to be responsible for the LDL cholesterol lowering benefit associated with soy.
  • These findings were published in the American Heart Associations journal Circulation in 2012.


How Lunasin Works (1:47)

Meet Our Research Leaders


Dr. Carl Hastings

Reliv Vice Chairman and Chief Scientific Officer

  • Ph.D. in Food Science from University of Illinois
  • Nearly 40 years in food product research and development
  • Conducted key research on nutritional food products and developed low-calorie foods marketed under the Weight Watchers label for Mead Johnson & Co.
  • Developed new applications for food ingredients developed from corn and soybeans at A.E. Staley Company
  • Joined Reliv International shortly after its founding in 1988
  • Created a comprehensive line of nutritional supplements and earned nine product patents
  • Member of board of directors of the Council for Responsible Nutrition
  • Ranked #9 out of more than 5,000 CSOs in 2012 according to ExecRank


Dr. Alfredo Galvez

Chief Scientific Officer at SL Tech, a Reliv Company

  • Ph.D. in Genetics from University of California, Davis
  • BS and MS degrees in Genetics and Plant Physiology from University of Philippines
  • Discovered the lunasin peptide in 1996 during postdoctoral research at University of California Berkley
  • Holds 8 patents on lunasin technology
  • 2013 Outstanding Alumni in Molecular Biology, University of the Philippines
  • Innovative Minds in Prostate Cancer Today (IMPaCT), US Dept. of Defense, 2011
  • 2010 Philippine Development (PhilDev) Foundation Awardee in Science and Engineering
  • American Association of Cancer Research (AACR) minority researcher awardee
  • Currently focused on the development of functional food and nutraceutical ingredients based on the lunasin peptide

Clinical Trials

Blood Glucose & Body Weight
  • Eight-week clinical trial consisting of 50 overweight adults.
  • Half of the subjects were given Reliv GlucAffect and half a non-active control product (placebo).
  • Subjects taking GlucAffect lowered their blood fasting glucose by an average of 30%.
  • No significant glucose lowering was found in the control group.
  • Those taking GlucAffect lost an average of nearly 16 pounds.
  • No significant effect on body weight was found in the control group.

Read Full Clinical Trial


Heart Health
  • In a clinical trial, Cardiosentials proved effective in significantly reducing two risk factors for heart disease and stroke: elevated cholesterol and elevated glucose.
  • Total cholesterol was lowered 7% and LDL was lowered 9%.
  • Triglycerides were decreased 13%
  • HDL (good cholesterol) increased 4%.
  • The ratio of bad to good cholesterol (LDL/HDL), another heart disease risk factor, declined 13%
  • Trial involved individuals taking statin medications and participants not taking statins.

Read Full Clinical Study


Heart Health
  • 60-day clinical study consisting of adult patients with lipid abnormalities
  • Reliv Now and FibRestore:
    • Proved effective in correcting lipid abnormalities and therefore may help in lowering the risk for cardiovascular disease.
    • Reduced average cholesterol by 14%.
    • Reduced average LDL by 18% and 8%, respectively.
    • Reduced average triglycerides by 1.2% and 12.4%, respectively.
    • Reduced average uric acid by 10.4% and 16.7%, respectively.
    • Greater reduction in cholesterol and triglycerides among diabetic or overweight individuals.

Read Full Clinical Study


Radiation-Induced Fatigue
  • Clinical study measuring the improvement in radiation-induced fatigue for cancer patients who used Reliv products for 1-4 weeks.
  • This was a “feasibility study,” and while the results were significant, their scientific accuracy would need to be vetted through a controlled trial.
  • Patients were given Reliv Classic and Innergize!
  • 75% of participants considered their result as helping their fatigue.
  • 25% of the entire group reported an “excellent” response.
  • There was no harm done to those who reported no response (except one with a few episodes of vomiting).

Read Full Clinical Trial


Weight Loss, Heart Health, and Metabolic Wellness
  • Eight-week clinical study of pigs supplemented with Reliv Now and LunaRich X.
  • The physiology of pigs is very similar to humans, especially in liver function.
  • Results included a decrease in weight gain and a 65% reduction in free fatty acid (FFA) levels, a biomarker associated with obesity and metabolic syndrome.
  • 64% increase in levels of leptin, a hormone that signals the brain when the body has had enough food, producing the feeling of fullness.
  • 60% increase in levels of adiponectin (ADP), a hormone from fat cells that controls energy metabolism.
  • There is no existing treatment for improving these three biomarkers (free fatty acids, leptin and adiponectin).
  • This study of Reliv Now in combination with LunaRich X yielded dramatic results in those areas.

Read Full Clinical Trial